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The clinical guideline recommends home monitoring for hypertension, diabetes, and 
hyperlipidemia maintenance therapy. The study aimed to compare the 10-year atherosclerotic 
cardiovascular disease (ASCVD) risk calculated using systolic blood pressure, fasting total-
cholesterol, and fasting blood sugar measured at the clinic and home. This analytical cross-sectional 
study was done in population from villages in Sleman District, Yogyakarta. The subjects were selected 
purposively with the criteria of 40-79 years old and signing the informed consent. The home-measured 
systolic blood pressure was monitored with a digital sphygmomanometer and peripheral finger-stick 
methods for cholesterol and blood sugar. On the same occasion, the clinic measurements were 
monitored with a mercury sphygmomanometer for systolic blood pressure, and with venous plasma 
analyzed in the laboratory for cholesterol and blood glucose. Measurements between methods were 
compared with paired T-tests. The subjects (n=171) had a mean age of 52.6 (8.1) years; 21.6% were 
male. The systolic blood pressure, total cholesterol, and blood glucose from clinic and home 
measurement were 130.0 (21.1) mmHg and 137.6 (22.4) mmHg (p<0.001); 202.8 (32.8) mg/dl and 
205.2 (44.8) mg/dl (p= 0.44); and 98.5 (42.9) mg/dl and 91.9 (34.6) mg/dl (p<0.001) respectively. The 
average ASCVD risks of the clinic and home measurements were 6.4 (6.2)% and 7.1 (6.9)% 
(p<0.001); however, both methods had the same ASCVD risk category at borderline risk (5-<7.5%). 
Conclusion: The ASCVD risk scores calculated using clinic and home measurements were statistically 
different. 
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Cardiovascular disease is the highest prevalence of non-communicable disease in Indonesia 
(Pariona, 2017). In 2015, the global morbidity rate and mortality rate of cardiovascular disease were 
estimated at 422.7 million (95% uncertainty interval: 415.5 to 427.9 million) and 17.9 million (95% 
uncertainty interval of 17.6 to 18.3 million) respectively (Roth et al., 2017). Atherosclerosis is 
responsible for cardiovascular diseases, namely coronary arterial disease, ischemic stroke, and 
peripheral arterial disease, recently known as Atherosclerotic Cardiovascular Diseases (ASCVD) 
(Grundy et al., 2019; Stone et al., 2015). Hypertension, hyperlipidemia, diabetes, and bad healthy 
lifestyles, including smoking, stressful life, sedentary life, and poor diet, are recognized as 
cardiovascular risk factors. These factors induce the development of atherosclerosis. Exposure to the 
risk factors accelerates atherosclerosis and the complex plaque-forming process. Atherosclerosis 
constricts blood vessels, blocks the blood flow, and produces serious health problems in some vital 
organs, e.g., heart, brain, and kidney (Douglas and Channon, 2014).  
The home measurement of blood pressure, total cholesterol, and fasting blood glucose is 
monitored by patients or their family members without health professional assistance. In contrast, 
healthcare professionals generally do the clinic measurement. A rural community is relatively far from 
health professionals and facilities. A study showed that capillary blood sugar levels could be used to 
replace venous blood sugar (Midilli et al., 2019). Maintenance of blood pressure, total cholesterol, and 
blood sugar target will reduce the atherosclerotic cardiovascular disease (ASCVD) risk, diabetes 
mellitus type 2, and stroke  (Riddle et al., 2018; Stone et al., 2015). The ASCVD risk can be predicted 
using the ASCVD calculation. The Pooled Cohort Equations (PCE) system is the newest version in the 
10-year ASCVD risk prediction and presented in percentage (Lloyd-Jones et al., 2019). Intervention 
for prevention and treatment for ASCVD can be provided for the intermediate and high-risk subjects 
as early as possible (Stone et al., 2015). 
Numerous studies had compared the clinic and home measurements with inconsistent results. 
However, no similar study in ASCVD risk comparison using clinic and home measurement values has 
been found from any journal database. This study was aimed to compare the ASCVD risk score 
calculated using the PCE method obtained from the clinic and home measurements of blood pressure, 
total cholesterol, and blood sugar among the rural community subjects. This research helps both 
subjects, doctors, and pharmacists, especially in rural areas, choose the best measurement method of 
an ASCVD risk score to get rapid intervention or education for subjects with an intermediate and high 
risk of ASCVD. Along with that, screening and monitoring the risk factor of ASCVD could be done 
earlier by pharmacists to reduce cardiovascular disease morbidity and mortality rates. 
 
MATERIALS AND METHOD 
Materials 
Case Report Form (CRF) was used to document the measurement and the subject's profiles, 
including the ASCVD parameters, namely age, sex, race, smoking status, diabetes status, and 
hypertension therapy status. The clinical SBP measurement was obtained from a mercury 
sphygmomanometer, while home SBP was measured using a digital sphygmomanometer (OMRON®). 
Home FBS was obtained using the instruments for the peripheral finger-stick blood sugar. Meanwhile, 
the home total cholesterol was measured using 1 set of Accu-check® and two (2) sets of Easytouch®. 
 
Methods 
The study was conducted with the observational method and done with the analytical cross-
sectional design. Data were collected among the subjects in Sleman District, Yogyakarta, Indonesia, 
under medical doctors' supervision. The research was conducted from June to August 2017. The 
subject's profiles were collected with written CRF. 
Pharmaciana ISSN: 2088 4559; e-ISSN: 2477 0256  
 






The subject selection was made with a purposive sampling method from the community in 
Sleman District.  The subject's criteria were adult, fasting for 8-10 hours before blood sampling, and 
agreed to participate in the study by signing informed consent. Whereas the excluded subjects were 
ones with a history of overt cardiovascular disease, pregnancy, or exceeded the permitted values of 
age, SBP, total cholesterol, or HDL-cholesterol. The minimum samples of subjects for paired T-test 
analysis were calculated with α (5%), β (20%), mean difference for ASCVD between method (δ) at 
0.5, and standard deviation (σ) at 1.5; resulted in 73 subjects per group (Dupont and Plummer, 1998). 
While minimum sample for moderately strong correlation (r>0.6; power 80%) was 17 subjects per 
group (Chan, 2005).  
Of the 205 subjects participated in the study, 34 subjects were excluded because suffered from 
ASCVD namely stroke (n=2), coronary arterial disease (n=2), and heart failure plus thyroid disease 
(n=1); and the data can not be calculated with ASCVD formula due to < 40 years old (n=13), high 
SBP at >200mmHg (n=4), high total cholesterol at >320mg/dl (n=6), low total cholesterol at 
<130mg/dl (n=4), and low HDL-cholesterol at <20mg/dl (n=2).  
Measurements of both blood pressure methods, home measurement of total cholesterol and 
FBS, were performed at the study sites. On the same occasion with peripheral blood sampling, the 
venous plasma samples for FBS, total-cholesterol, HDL-cholesterol levels for clinic measurement 
were conducted in the study sites by the laboratory technician and transported to P (anonymous) 
Laboratory®  for the blood chemical assay. The clinic FBS was determined with the plasma hexokinase 
method, whereas the total-cholesterol concentration was determined with the CHOD-PAP method. 
Before conducting the study, the measurement instruments used in this study, including the 
CRF, were validated to ensure a valid and reliable measurement. The CRF was tested on some 
volunteers to assess the subject's understanding of the content. In addition, the validation of 
sphygmomanometer had been validated by the external calibrator.   
Several field data collectors did the SBP of clinic measurement, and the SBP measurements 
were likely to have different perceptions among observers. Therefore, the reliability tests between 
observers were necessary done in three subjects with triple replication for each observer. After that, 
the data were analyzed using paired T-tests. The paired T-tests had p-values at >0.05, which indicated 
no difference of perception between observers.  
The reliability tests for the instruments of total cholesterol and fasting blood glucose were done 
in 3 subjects with triple replication. The coefficient variance (CV) value within the instrument was 
then calculated. The mean CV of the reliability test for Accu-check® was 2.9 (3.2%), while the mean 
CV for two sets of EasyTouch® was 5.6 (1.9%) and 4.5 (7.1%). The standard CV value within the 
instrument should be below 5-10% based on the standard CV criteria, which states that instruments 
with fewer than five replications should be valid for imprecision levels at <5–10% CV (Davis et al., 
2013).  
The 10-year prediction of ASCVD risk score was measured using the online calculator of 
ASCVD Risk Estimator. The ASCVD risk was categorized as a low risk at <5%, borderline risk at 
5%-<7.5%, intermediate risk at 7.5%-<20%, and high risk at ≥20%. The calculator is applicable only 
for the following variables, namely age of 40-79 years, SBP at 90-200mmHg,  DBP at 60-130mmHg, 
total cholesterol at 130-320mg/dl, HDL-cholesterol at 20-100mg/dl, and LDL-cholesterol at 30-
300mg/dl (Lloyd-Jones et al., 2019). In this study, the discussion focused on the variables of SBP, 
total cholesterol, and HDL-cholesterol.  
The validity tests for home methods of SBP, total-cholesterol, FBS, and 10-year ASCVD risk 
score were conducted to compare with those values from clinic methods and analyzed with paired 
numerical comparative tests, namely paired T-tests.  Prior to the T-test, the normality of data 
distribution was done using the Kolmogorov-Smirnov Test. The clinic and home measurements for 
SBP, total-cholesterol, FBS, and ASCVD risk showed that the data distribution was not normal 
(normality test result with p-value<0.001). According to the central limit theorem, the sample size with 
30 and more subjects can be assumed to be normal distribution population regardless of the 
                ISSN: 2088 4559; e-ISSN: 2477 0256 






distribution result (Kwak and Kim, 2017). Based on the central limit theorem, the analysis for ASCVD 
risk was done with paired T-test. 
The agreement between the clinic and home measurements on categorizing diabetic subjects 
was carried out with the Kappa test, and the sensitivity and specificity levels were analyzed with a 
home method. The sensitivity and specificity were obtained with one minus false-negative rate (1-
FNR) and one minus false-positive rate (1-FPR), respectively. All hypotheses were analyzed under 
95% significant statistics. The statistical data were analyzed by an external statistician in Clinical 
Epidemiology & Biostatistics Unit Study Center (CEBU) Universitas Gadjah Mada using the IBM 
SPSS Statistics 22 program.  
 
Ethics statement  
This study was done with the ethical clearance No. 436/C.16/FK/2017 and 437/C.16/FK/2017 
issued by Medical Research and Medical Ethics Committee of Faculty of Medicine, Universitas 
Kristen Duta Wacana, Indonesia. This study was done with a descriptive method. The subjects were 
described with the study procedure and requested to sign informed consent before the study was 
conducted. The possible harm was infection and bruise at the blood-sampling site. This adverse effect 
was minimized with the aseptic sampling technique by the laboratory staff. In this study and its 
publication, all subjects were treated as anonymous.  
 
RESULTS AND DISCUSSION 
This study aimed to compare the 10-year ASCVD risk scores using the clinic and home 
measurements of SBP, FBS, and fasting total-cholesterol measurements. The substitution from the 
clinic measurement to the home measurement for ASCVD risk calculation has the purpose of early 
risk detection, particularly for the subjects from a rural community or far from a health facility. The 
portable digital instruments of SBP, total cholesterol, and FBG were generally available at home in the 
community. Whereas the SBP, total cholesterol, and FBG are the ASCVD risk components of the PCE 
method. Parameters from clinical measurements are the golden standard to diagnose ASCVD risk. 
However, home measurements are more practical for subjects in monitoring the ASCVD parameters. 
Subjects who were particularly far from health access will obtain advantages if the ASCVD risk can be 
monitored using home measurement. The clinician has used the ASCVD risk to initiate statin therapy 
for the high-risk subjects since 2013 (Stone et al., 2015).  
 
Subjects' characteristics 
The ASCVD parameters other than SBP, total cholesterol, and blood sugar in overall subjects 
(n=171) were described as follow: few male subjects (21.6%), high prevalence of smokers (52.0%), 
hyperglycemia subjects (9.9%), hypertension therapy receivers (19.9%), and non-white/black race 
subjects (100%); mean age of 52.6 (8.1) years old; with relatively high total-cholesterol and/or LDL-
cholesterol; with relatively normal average fasting blood glucose; and with average SBP/DBP higher 
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Table 1. Subjects' characteristics of ASCVD risk component 
Subject's Characteristics Results 
Male n (%) 37 (21.6) 
Smoking statusa) n (%) 89 (52.0) 
Hyperglycemia n (%) 17 (9.9) 
Therapy of hypertension status n 
(%) 
34 (19.9) 
Age: mean (SD) 52.6 (8.1) y.o. 
Total-Cholesterol: mean (SD) 202.8 (32.8) mg/dl 
LDL-C: mean (SD) 129.8 (29.5) mg/dl 
HDL-C: mean (SD) 50.9(12.7) mg/dl 
FBG: mean (SD) 98.5 (42.9) mg/dl 
SBP: mean (SD) 130.0 (21.1) mmHg 
DBP: mean (SD) 83.8 (10.4) mmHg 
 
Note: a)Recently active/passive smoking; LDL-C= Low Density 
Lipoprotein-Cholesterol; HDL-C=High Density Lipoprotein-Cholesterol; 
FBG= Fasting Blood Glucose; SBP= systolic blood pressure; DBP 
diastolic blood pressure; SD= Standard Deviation; non-white/black 
subjects=100%  
 
Clinic versus home blood pressure, total-cholesterol, and fasting blood glucose 
The SBP's sub-groups were categorized based on ACC/AHA guidelines. The home 
measurement results for SBPs were significantly higher than the clinic SBP (p<0.001) in the total 
subjects and the SBP sub-groups. Similar results of higher home DBP were found in total subjects and 
in sub-groups <90mmHg with clinic measurement (p<0.05), but in the subjects with ≥90mmHg DBP 
had insignificant higher home DBP than clinic DBP. This study's finding had the opposite results from 
the previous studies showed that the mean SBP from clinic measurement was higher than the home 
measurement (Myers et al., 2008; Nargesi et al., 2014). Home (digital) sphygmomanometers often use 
oscillometry techniques, similar to auscultation used in clinical (mercury) sphygmomanometers. 
Auscultation technique needs a professional's skill owned by healthcare personnel (Pickering et al., 
2005). Therefore, digital sphygmomanometer usage is more patient-friendly and more frequently used 
in self-monitoring of SBP/DBP at home by the patients. 
Some factors can affect BP measurements, causing differences between home and clinic BP 
monitoring results. According to American Diagnostic Corporation (2008), the first factor which 
possibly affects the result is the sitting duration (American Diagnostic Corporation, 2008). The longer 
the subject sits waiting for BP to be measured, the more probable they are relaxed, and their BPs are 
more stabilized. As recommended by American Heart Association (AHA) and the British 
Hypertension Society (BHS), patients need to be seated without talking for more or less five minutes 
before the measurement. Nevertheless, apart from a thoughtful recommendation, other factors that can 
interfere with the measurements depend on patients' conditions, such as their stress level, physiology, 
and activities done prior to the measurement. In fact, the first measurement will likely result in 
relatively higher than the following measurements despite the resting interval. Another factor to 
consider was the difference in blood pressure cuffs size from two different sphygmomanometers. The 
cuff that is too small will overestimate the BP. Based on a study that focuses on cuff application, too 
small cuff justified 84% of cuff sizing errors, which is dramatically more significant than the errors 
due to the too large cuff size.  
Furthermore, the difference between using home and clinic measurements identifies the patients 
with white-coat hypertension or masked hypertension. Patients with white-coat hypertension 
experience high BP only in the clinic measurement, whereas individuals with masked hypertension 
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have elevated BP only in the home measurement (Unger et al., 2020). White-coat hypertension and 
masked hypertension are caused by a particular environment that results in inaccurate blood pressure 
readings. White-coat hypertension indicates that the patients result in relatively high blood pressure 
when doctors or clinicians check it at doctor's practices but not at home. It is defined with clinical 
systolic BP≥140 mmHg and/or diastolic BP≥90 mmHg measurement and showed home systolic 
BP<135 mmHg and diastolic BP<85 mmHg. On the other hand, masked hypertension implies 
contrasting situations where the patients encounter high blood pressure at different environments than 
doctor's practices, such as at home. It is defined with home systolic BP≥135 mmHg and/or diastolic 
BP≥85 mmHg, whereas it showed clinical systolic BP<140 mmHg and diastolic BP<90 mmHg 
measurement (Stergiou et al., 2014). Commonly, these conditions exist among untreated or treated 
subjects for hypertension. It is also shown that about 10% - 30% of individuals who come to the 
clinics due to high blood pressure have white coat hypertension, and 10% - 15%  possess masked 
hypertension (Unger et al., 2020). 
The clinic and the home measurements of total cholesterol in the overall subjects were 202.8 
(32.8) mg/dl and 205.2(44.8) mg/dl (p=0.44). The clinic and home total cholesterol measurements had 
inconsistent differences with higher and lower values than home measurements. Though the 
measurements were not significantly different, the home measurement was not recommended for 
substitution because it had the lowest correlation coefficient among other variables. This study's results 
were different from the previous study, which stated that total cholesterol was insignificantly higher 
than clinic measurement (Sblendorio et al., 2008). The clinic and home measurements use different 
samples in measurements; the cholesterol distribution in the lymphatic fluid or interstitial on the 
peripheral vascular system was 10% of the plasma's cholesterol (Greenland et al., 1990). Given the 
above description, the cholesterol level in peripheral vascular used in the home measurement should 
be lower than the clinic method. 
The clinic-measured and home-measured FBS in total subjects were 98.5 (42.9)mg/dl and 91.9 
(34.6)mg/dl (p<0.001). Significantly lower home-measured FBGs were found in FBG sub-group of 
<100mg/dl, ≥126mg/dl sub-groups, and in total subjects; except for 100-125mg/dl with an 
insignificantly different value. The result was different from the previous studies, in which the blood 
sugar level obtained from the clinic was lower than the home measurement (Boyd et al., 2005; Midilli 
et al., 2019). A study with a higher value of capillary whole blood sugar level done using the 2-hour 
OGTT had an increase of 0.8 mmol/L sugar level compared to the method measured using venous 
laboratory plasma sugar (Blaurock et al., 2018). The clinic measurement for blood sugar used the 
blood plasma, whereas the home measurement used the whole blood. Plasma used in the clinic 
measurement has higher water composition; thereby, it has higher blood sugar levels (Patel and Patel, 
2015; Rajaratnam and Pathmanathan, 2012). The Kappa test result with the Kappa coefficient at 0.959, 
p<0.001, showed a very good agreement in determining diabetes status between the clinic and home 
methods.  Both clinic and home methods measurements showed no difference in diabetes prevalence 
due to similar categorizations of diabetic or non-diabetic subjects. The home-measured FBG in this 
study also had high sensitivity and specificity rate.  
The correlation coefficient (r) interpretation (Chan, 2005) of the clinic and home measurements 
from the highest to the lowest correlations were: FBG (r: 0.959, p<0.001 categorized as very strong 
correlation), SBP (r: 0.898, p<0.001, very strong), DBP (r:0.752, p<0.001, moderately strong 
correlation), and total-cholesterol (r: 0.499, p<0.001, fair correlation). The clinic and home 
measurements have a strong agreement in the determination of diabetes. The home measurement also 
had high sensitivity and specificity rate in the determination of diabetes as compared with the clinic 
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Table 2. Comparison systolic blood pressure (SBP), diastolic blood pressure, total-cholesterol, 






Systolic Blood Pressure or SBP (mmHg) 
<120 (n=45) 106.2 (5.6) 116.9 (11.2) <0.001 
120-129 (n=37) 120.1 (0.8) 125.8 (8.8) <0.001 
130-139 (n=28) 130.2 (0.9) 137.1 (8.3) <0.001 
≥ 140 (n=61) 153.4 (14.1) 160.4 (17.8) <0.001 
Total subjects 130.0 (21.1) 137.6 (22.4) <0.001 
In total subjects correlation (r) SBP: 0.898; p-value: <0.001 
Note: SBPs were based on ACC/AHA guidelines (Whelton et al., 2017). 
Diastolic Blood Pressure or DBP (mmHg) 
<80 (n=30) 68.6 (4.3) 73.3. (7.8) 0.003 
80-89 (n=72) 80.1 (0.6) 82.3 (7.7) 0.01 
≥ 90 (n=69) 94.4 (5.7) 95.5 (10.4) 0.25 
Total subjects 83.8 (10.4) 86.1 (12.2) <0.001 
In total subjects correlation (r) DBP: 0.752; p-value: <0.001 
Total-cholesterol or T-C (mg/dl) 
<200 (n=85) 176.7 (16.3) 185.6 (32.0) 0.01 
200-<240 (n=61) 216.6 (12.7) 217.5 (44.3) 0.87 
≥240(n=25) 257.8 (15.5) 241.7 (51.3) 0.13 
Total subjects 202.8 (32.8) 205.2 (44.8) 0.44 
In total subjects correlation (r) T-C: 0.499; p-value: <0.001 
Fasting Blood Glucose or FBG (mg/dl) 
<100 (n=138) 83.8 (7.3) 80.2 (8.9) <0.001 
100-125 (n=16) 106.4 (5.5) 100.8 (17.6) 0.19 
≥126 (n=17) 210.6 (61.2) 179.1 (48.9) <0.001 
Total Subjects 98.5 (42.9) 91.9 (34.6) <0.001 
In total subjects correlation (r) FBG: 0.959; p-value: <0.001 
Determination of DM with home measurement: sensitivity = 1-FNR 
= 0.941; specificity= 1-FPR = 0.994; FNR= false negative rate; and 
FPR = false positive rate.  
Kappa coefficient for DM threshold=0.935; p<0.001 very strong 
agreement between clinic and home measurement (Gisev et al., 
2013)  
Note:  
Clinic-measurements consisted of blood pressure with a mercury sphygmomanometer, total 
cholesterol, and Fasting Blood Glucose using the vena sample and analyzed in a laboratory. Home 
measurement consisted of blood pressure with a digital sphygmomanometer, total-cholesterol, and 
Fasting Blood Glucose using finger-stick samples and measured with portable home instruments. 
 
ASCVD risk score from clinic and home measurement 
The mean ASCVD risk score from clinic measurement for all instruments in total subjects was 
6.4 (6.2)%, whereas the mean score from home measurement was 7.1 (6.9)% (p=0.001). Substitution 
of a single parameter of ASCVD risk with home-measured SBP while the remaining parameters with 
clinic measurements have the result of the ASCVD score at 7.1 (6.9)%; significantly different from the 
standard clinic measurement (p<0.001). Similar substitution for single measurement home-measured 
FBS and total cholesterol results were 6.4 (6.2)% (p:0.85) and 6.4 (6.2)% (p:0.56); not significantly 
different from standard measurement. However, the ASCVD measurements from four observed 
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methods were classified in the same category: borderline risk in the range of 5%-7.5%.  In ASCVD 
subgroup analysis, the home measurement had significantly different ASCVD risk from the standard 
clinic measurement except for high-risk subjects. Nevertheless, the high-risk subgroup had only 7 
subjects and needed further confirmation. The results shown above indicate statistical differences but 
were not reflected on the clinical ASCVD risk stratification. Furthermore, in ASCVD subgroup 
analysis, the substitution of the single parameter of SBP but not total-cholesterol or FBG had resulted 
in significantly different ASCVD risk scores from the clinic measurement (Table 3). 
Mean ASCVD risk score calculated using clinic and home measurement were significantly 
different (p=0.001). The ASCVD risk derived from home-measured SBP, total cholesterol, and blood 
sugar measurement cannot represent the standard measurement in a normal setting for ASCVD risk 
determination. The home-measured SBP was significantly different when implemented in the ASCVD 
risk score calculation, whereas the results were not significantly different with home-measured total 
cholesterol and FBG. The home-measured FBG substitution was likely the best among the two other 
variables. In the total subjects, the mean home and clinic measurement of SBP, total cholesterol, and 
FBG had the same risk category. In this study, the home measurement can be recommended as the 
secondary alternative for monitoring and evaluation therapy temporarily when the clinic measurement 
was not available. When the home measurement was used to temporarily substitute the clinic 
measurement for early detection of the component of ASCVD risk, the clinic measurement should 
reconfirm the result at the soonest. A study of peripheral or finger-stick method clinical use in the 
measurement of subject's cholesterol level showed that the method is appropriate to detect subject's 
hyperlipidemia and meet the criteria for cardiovascular disease prevention  (Parikh et al., 2009).  
The mean ASCVD risk using clinic measurement was 6.6 (5.9)%, which indicated that the 
subjects were at borderline cardiovascular risk (5%-<7.5%). The ASCVD risk was similar to previous 
research done in the villages in Sleman District, Yogyakarta. The previous study showed the subjects 
had moderate CVD risk calculated using Framingham Score at 11.4(8.9)% (Suhadi et al., 2017).  
Some limitations technically occurred in this study; home method instrument for HDL-
cholesterol had not been available yet in the community. The HDL-cholesterol level as a component in 
the calculation of ASCVD risk was obtained from clinic measurement. The number of subjects for the 
analysis in sub-groups was insufficient and different in each sub-group, though the total subjects met 
the study's minimum sample. Due to the limitation mentioned above, the results were not likely to be 
implemented in other settings or when the standard measurement facilities were available. Further 
study is needed to compare clinic-measured and home-measured SBP, total cholesterol, blood sugar 
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Table 3. ASCVD risk comparison between clinic and home measurement and a single systolic 




Correlation coefficient (r) between ASCVD from standard (clinic) and home measurement: r= 0.950, p-
value <0.001. 
SBP= Systolic Blood Pressure; TC= total cholesterol; FBG=fasting blood glucose; low, borderline, 
intermediate, and high risk = <5%; 5%-<7.5%; 7.5%-<20%; ≥20% ASCVD 10-year risk score;  




The ASCVD risk scores calculated using the PCE method obtained from clinic-measured and 
home-measured blood pressure, total cholesterol, and fasting blood sugar were significantly different 
at 6.4 (6.2) versus 7.1 (6.9) with p-value=0.001, but similarly categorized at borderline risk. 
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